Cargando…
Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Georg Thieme Verlag KG
2021
|
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837412/ https://www.ncbi.nlm.nih.gov/pubmed/35169775 http://dx.doi.org/10.1055/s-0041-1736239 |
| _version_ | 1784649903363850240 |
|---|---|
| author | Diao, Fei-Yu |
| author_facet | Diao, Fei-Yu |
| author_sort | Diao, Fei-Yu |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8837412 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Georg Thieme Verlag KG |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88374122022-02-14 Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer Diao, Fei-Yu Glob Med Genet Georg Thieme Verlag KG 2021-10-05 /pmc/articles/PMC8837412/ /pubmed/35169775 http://dx.doi.org/10.1055/s-0041-1736239 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. ( https://creativecommons.org/licenses/by/4.0/ ) https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Diao, Fei-Yu Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer |
| title | Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer |
| title_full | Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer |
| title_fullStr | Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer |
| title_full_unstemmed | Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer |
| title_short | Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer |
| title_sort | alpelisib: a well-tolerated treatment option for patients with hr-positive, her2-negative, pik3ca-mutated advanced breast cancer |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837412/ https://www.ncbi.nlm.nih.gov/pubmed/35169775 http://dx.doi.org/10.1055/s-0041-1736239 |
| work_keys_str_mv | AT diaofeiyu alpelisibawelltoleratedtreatmentoptionforpatientswithhrpositiveher2negativepik3camutatedadvancedbreastcancer |